SG10201606484SA - Binding molecules for bcma and cd3 - Google Patents

Binding molecules for bcma and cd3

Info

Publication number
SG10201606484SA
SG10201606484SA SG10201606484SA SG10201606484SA SG10201606484SA SG 10201606484S A SG10201606484S A SG 10201606484SA SG 10201606484S A SG10201606484S A SG 10201606484SA SG 10201606484S A SG10201606484S A SG 10201606484SA SG 10201606484S A SG10201606484S A SG 10201606484SA
Authority
SG
Singapore
Prior art keywords
bcma
binding molecules
molecules
binding
Prior art date
Application number
SG10201606484SA
Other languages
English (en)
Inventor
Peter Kufer
Tobias Raum
Patrick Hoffmann
Roman Kischel
Ralf Lutterbuese
Doris Rau
Paul Adam
Eric Borges
Barbara Hebeis
Susanne Hipp
Original Assignee
Amgen Res Munich Gmbh
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47388493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201606484S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh, Boehringer Ingelheim Int filed Critical Amgen Res Munich Gmbh
Publication of SG10201606484SA publication Critical patent/SG10201606484SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201606484SA 2011-11-15 2012-11-15 Binding molecules for bcma and cd3 SG10201606484SA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161560149P 2011-11-15 2011-11-15
US201161560162P 2011-11-15 2011-11-15
US201161560178P 2011-11-15 2011-11-15
US201161560144P 2011-11-15 2011-11-15
US201161560183P 2011-11-15 2011-11-15
US201261651474P 2012-05-24 2012-05-24
US201261651486P 2012-05-24 2012-05-24

Publications (1)

Publication Number Publication Date
SG10201606484SA true SG10201606484SA (en) 2016-10-28

Family

ID=47388493

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201704483RA SG10201704483RA (en) 2011-11-15 2012-11-15 Binding molecules for bcma and cd3
SG11201400671YA SG11201400671YA (en) 2011-11-15 2012-11-15 Binding molecules for bcma and cd3
SG10201606484SA SG10201606484SA (en) 2011-11-15 2012-11-15 Binding molecules for bcma and cd3
SG11201401729PA SG11201401729PA (en) 2011-11-15 2012-11-15 Binding molecules for bcma and cd3

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201704483RA SG10201704483RA (en) 2011-11-15 2012-11-15 Binding molecules for bcma and cd3
SG11201400671YA SG11201400671YA (en) 2011-11-15 2012-11-15 Binding molecules for bcma and cd3

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201401729PA SG11201401729PA (en) 2011-11-15 2012-11-15 Binding molecules for bcma and cd3

Country Status (39)

Country Link
US (7) US9150664B2 (fr)
EP (4) EP2780374B1 (fr)
JP (5) JP6231007B2 (fr)
KR (4) KR102346029B1 (fr)
CN (3) CN104114578B (fr)
AP (1) AP2014007529A0 (fr)
AR (1) AR088883A1 (fr)
AU (1) AU2012327203A1 (fr)
BR (2) BR112014010940A2 (fr)
CA (2) CA2849196C (fr)
CL (1) CL2014001254A1 (fr)
CY (1) CY1122543T1 (fr)
DK (1) DK2780375T3 (fr)
EA (2) EA028162B1 (fr)
EC (2) ECSP14004829A (fr)
ES (2) ES2749451T3 (fr)
FR (1) FR23C1013I1 (fr)
GE (1) GEP20186928B (fr)
HR (1) HRP20191697T1 (fr)
HU (1) HUE046682T2 (fr)
IL (3) IL232603B (fr)
LT (1) LT2780375T (fr)
MA (2) MA35450B1 (fr)
ME (1) ME03521B (fr)
MX (2) MX349396B (fr)
MY (1) MY189544A (fr)
PE (1) PE20141564A1 (fr)
PH (1) PH12014501091A1 (fr)
PL (1) PL2780375T3 (fr)
PT (1) PT2780375T (fr)
RS (1) RS59373B1 (fr)
SG (4) SG10201704483RA (fr)
SI (1) SI2780375T1 (fr)
TN (2) TN2014000097A1 (fr)
TW (1) TWI679212B (fr)
UA (1) UA116766C2 (fr)
UY (2) UY34453A (fr)
WO (2) WO2013072415A1 (fr)
ZA (1) ZA201401615B (fr)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX338038B (es) * 2008-10-01 2016-03-30 Amgen Res Munich Gmbh Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas.
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2817338B1 (fr) 2012-02-24 2017-07-26 AbbVie Stemcentrx LLC Modulateurs de dll3 et leurs procédés d'utilisation
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2762496A1 (fr) * 2013-02-05 2014-08-06 EngMab AG Procédé pour la sélection d'anticorps contre BCMA
EP3620468A1 (fr) * 2013-02-05 2020-03-11 EngMab Sàrl Procédé de sélection d'anticorps contre bcma
ME03394B (fr) 2013-02-22 2020-01-20 Medimmune Ltd Nouveaux conjugués anticorps et leurs utilisations
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
RU2016111131A (ru) 2013-08-28 2017-10-03 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Способы конъюгации сайт-специфических антител и композиции
CA2926428C (fr) * 2013-10-09 2023-08-29 Research Development Foundation Anticorps monoclonaux anti-olfml-3 et leurs utilisations
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
AU2015213437B2 (en) 2014-02-07 2018-04-05 Mcmaster University Trifunctional T cell-antigen coupler and methods and uses thereof
EP3107576A4 (fr) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anticorps anti-dll3 et conjugués de médicaments destinés à être utilisés dans un mélanome
EP3110838B1 (fr) * 2014-02-27 2019-06-26 UCL Business Plc. Variants d'april
EP3131927B8 (fr) * 2014-04-14 2020-12-23 Cellectis Récepteurs antigéniques chimériques spécifiques de bcma (cd269), utiles dans l'immunothérapie du cancer
WO2016001810A1 (fr) 2014-07-01 2016-01-07 Pfizer Inc. Diabodies hétérodimères bispécifiques et leurs utilisations
EP2982692A1 (fr) * 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
CA2963696A1 (fr) * 2014-10-09 2016-04-14 Engmab Ag Anticorps bispecifiques diriges contre cd3epsilon et ror1 a utiliser dans le traitement du cancer des ovaires
EP3023437A1 (fr) * 2014-11-20 2016-05-25 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
PL3221357T3 (pl) * 2014-11-20 2020-11-02 F. Hoffmann-La Roche Ag Wspólne łańcuchy lekkie i sposoby zastosowania
EP3029068A1 (fr) * 2014-12-03 2016-06-08 EngMab AG Anticorps bispécifiques contre du CD3epsilon et BCMA pour utilisation dans le traitement de maladies
EP3227432B1 (fr) 2014-12-05 2023-10-11 Memorial Sloan Kettering Cancer Center Récepteurs antigéniques chimériques ciblant l'antigène de maturation des cellules b et leurs utilisations
CN113388036A (zh) * 2014-12-05 2021-09-14 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
WO2016138175A1 (fr) * 2015-02-24 2016-09-01 The University Of British Columbia Système microfluidique à flux continu
KR102405104B1 (ko) 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
MX2017013298A (es) 2015-04-13 2018-06-19 Pfizer Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
EP4345112A2 (fr) * 2015-05-13 2024-04-03 Ablynx N.V. Polypeptides de recrutement de lymphocytes t basés sur la réactivité à cd3
IL255697B2 (en) * 2015-05-18 2023-11-01 Tcr2 Therapeutics Inc Compositions and methods for TCR programming using fusion proteins
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
WO2017021450A1 (fr) * 2015-08-03 2017-02-09 Engmab Ag Anticorps monoclonaux dirigés contre bcma
AU2016304764C1 (en) 2015-08-07 2023-06-01 Imaginab, Inc. Antigen binding constructs to target molecules
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
HUE050556T2 (hu) * 2015-08-17 2020-12-28 Janssen Pharmaceutica Nv Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
CN108026521B (zh) 2015-09-24 2022-12-06 第一三共株式会社 抗garp抗体
EP4285923A3 (fr) 2015-11-25 2024-03-06 Visterra, Inc. Molécules d'anticorps se liant à april et leurs utilisations
TWI797073B (zh) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
HUE057220T2 (hu) 2016-02-03 2022-04-28 Amgen Res Munich Gmbh BCMA és CD3 bispecifikus, T-sejtet kötõ antitest-konstrukciók
CA3011942A1 (fr) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Constructions d'anticorps impliquant des cellules t bispecifiques psma et cd3
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
PL3433280T3 (pl) 2016-03-22 2023-07-31 F. Hoffmann-La Roche Ag Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
BR112018070159A2 (pt) * 2016-04-01 2019-04-30 Kite Pharma, Inc. moléculas de ligação de bcma e métodos de uso das mesmas
JP7010491B2 (ja) 2016-04-11 2022-01-26 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク ヒト化抗ｒａｇｅ抗体
CA3024683A1 (fr) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Proteines se liant au fragment monocatenaire variable de cd3
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3471773A4 (fr) 2016-06-21 2020-07-08 Teneobio, Inc. Anticorps se liant à cd3
WO2018014260A1 (fr) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CR20190198A (es) * 2016-09-14 2019-10-11 Teneobio Inc Anticuerpos de unión a cd3
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
WO2018068201A1 (fr) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et ses variants contre ctla-4
BR112019008426A2 (pt) 2016-11-02 2019-09-03 Engmab Sarl anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
WO2018087557A1 (fr) * 2016-11-11 2018-05-17 Autolus Limited Récepteur d'antigène chimère
WO2018098365A2 (fr) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions et méthodes de reprogrammation de tcr au moyen de protéines de fusion
AU2017363302A1 (en) 2016-11-23 2019-06-27 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
KR20210087108A (ko) 2016-11-23 2021-07-09 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
MX2019007379A (es) 2016-12-21 2019-09-18 Teneobio Inc Anticuerpos anti-bcma unicamente de cadena pesada.
EP3577134A1 (fr) 2017-01-31 2019-12-11 Novartis AG Traitement du cancer à l'aide de protéines chimères du récepteur de lymphocytes t ayant de multiples spécificités
CN110461361A (zh) * 2017-02-10 2019-11-15 蜻蜓治疗公司 结合bcma、nkg2d和cd16的蛋白
CN117357638A (zh) 2017-02-17 2024-01-09 弗雷德哈钦森癌症中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
EP3589662A4 (fr) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Protéine monovalente inductible de fixation d' antigène
EP3589655B1 (fr) 2017-02-28 2022-10-26 Affimed GmbH Diabody en tandem pour l'engagement de cellules nk dirigées contre cd16a
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
EP3615055A1 (fr) 2017-04-28 2020-03-04 Novartis AG Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
EP3621994A4 (fr) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. Protéines de liaison à la mésothéline
BR112019023856A2 (pt) 2017-05-12 2020-06-09 Harpoon Therapeutics Inc proteínas triespecíficas que visam msln e métodos de utilização
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
WO2019000223A1 (fr) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. Activateurs de cellules effectrices immunitaires d'anticorps chimériques et leurs procédés d'utilisation
MX2020001328A (es) 2017-08-03 2020-03-20 Amgen Inc Muteinas de interleucina 21 y metodos de tratamiento.
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
UY37870A (es) 2017-09-08 2019-03-29 Amgen Inc Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
JP2020533382A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
CA3075717A1 (fr) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Polytherapie pour le traitement du cancer
CA3075716A1 (fr) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Polytherapie pour le traitement du cancer
EP3694997A4 (fr) 2017-10-12 2021-06-30 Mcmaster University Coupleur d'antigènes de lymphocytes t à mutation y182t et procédés et utilisations de celui-ci
BR112020007249B1 (pt) 2017-10-13 2022-11-22 Harpoon Therapeutics, Inc Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas
BR112020007196A2 (pt) * 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
JP2021501570A (ja) 2017-10-18 2021-01-21 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
MX2020004243A (es) 2017-11-01 2020-09-25 Juno Therapeutics Inc Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
WO2019099639A1 (fr) 2017-11-15 2019-05-23 Navartis Ag Récepteur d'antigène chimérique ciblant bcma, récepteur d'antigène chimérique ciblant cd19, et polythérapies
WO2019108900A1 (fr) 2017-11-30 2019-06-06 Novartis Ag Récepteur d'antigène chimérique ciblant le bcma et ses utilisations
KR20200104342A (ko) 2017-12-22 2020-09-03 테네오바이오, 인코포레이티드 Cd22에 결합하는 중쇄 항체
CN111886250A (zh) * 2017-12-27 2020-11-03 特尼奥生物股份有限公司 CD3-δ/ε异二聚体特异性抗体
CA3082280A1 (fr) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Anticorps a domaine unique et leurs variants diriges contre tigit
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
JP7366908B2 (ja) 2018-01-15 2023-10-23 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｐｄ－１に対する単一ドメイン抗体及びその変異体
AU2019211326A1 (en) * 2018-01-23 2020-09-10 Nextcure, Inc. B7-H4 antibodies and methods of use thereof
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (fr) 2018-02-13 2020-12-23 Novartis AG Thérapie par récepteur antigénique chimérique en combinaison avec il-15 r et il15
EP3759146A1 (fr) 2018-03-02 2021-01-06 CDR-Life AG Protéines de liaison à un antigène trispécifiques
CN116836297A (zh) 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
KR20200143436A (ko) * 2018-04-13 2020-12-23 아피메트 게엠베하 Nk 세포 결합 항체 융합 구조체
EP3802611A2 (fr) 2018-06-01 2021-04-14 Novartis AG Molécules de liaison dirigées contre bcma et leurs utilisations
CN112533633A (zh) * 2018-06-08 2021-03-19 伊麦吉纳博公司 Cd4的抗原结合构建体
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
MA53168A (fr) 2018-07-19 2021-05-26 Regeneron Pharma Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations
US20210284732A1 (en) * 2018-07-31 2021-09-16 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
EP3843757B1 (fr) * 2018-08-27 2024-04-24 Affimed GmbH Cellules nk cryopreserves prechargees d'un construction anticorps
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
US11590223B2 (en) 2018-08-31 2023-02-28 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
EP3844267A2 (fr) 2018-08-31 2021-07-07 Novartis AG Procédés de fabrication de cellules exprimant un récepteur d'antigène chimère
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
TW202028239A (zh) * 2018-09-28 2020-08-01 美商安進公司 針對可溶性bcma之抗體
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
EP3874272A1 (fr) 2018-10-31 2021-09-08 GlaxoSmithKline Intellectual Property Development Limited Procédés de traitement du cancer
PE20211867A1 (es) * 2018-11-01 2021-09-21 Shandong New Time Pharmaceutical Co Ltd Anticuerpos biespecificos y su uso
AU2020229806A1 (en) 2019-02-25 2021-07-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (fr) 2019-03-21 2020-09-24 Novartis Ag Thérapies par cellules car-t à efficacité améliorée
AU2020240132A1 (en) 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
EP3953455A1 (fr) 2019-04-12 2022-02-16 Novartis AG Procédés de fabrication de cellules exprimant un récepteur antigénique chimérique
EP3959320A1 (fr) 2019-04-24 2022-03-02 Novartis AG Compositions et procédés de dégradation sélective de protéines
PE20220575A1 (es) 2019-06-14 2022-04-20 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3
CA3144324A1 (fr) * 2019-06-24 2020-12-30 Novartis Ag Schema posologique et polytherapies pour des anticorps multispecifiques ciblant un antigene de maturation des lymphocytes b
WO2021004400A1 (fr) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 Complexe anticorps-récepteur cd3 exprimant une cellule immunitaire et son utilisation
CN112204135A (zh) * 2019-07-06 2021-01-08 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
EP4010372A2 (fr) 2019-08-06 2022-06-15 GlaxoSmithKline Intellectual Property Development Limited Compositions biopharmaceutiques et procédés associés
KR20220085779A (ko) * 2019-09-25 2022-06-22 페이트 세러퓨틱스, 인코포레이티드 다중-표적화 효과기 세포 및 이의 용도
EP3819007A1 (fr) 2019-11-11 2021-05-12 Amgen Research (Munich) GmbH Régime de dosage pour agents anti-bcma
JP2023503163A (ja) 2019-11-26 2023-01-26 ノバルティス アーゲー キメラ抗原受容体及びその使用
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
CA3170833A1 (fr) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Proteines de liaison a flt3 et methodes d'utilisation
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
WO2021173985A2 (fr) 2020-02-27 2021-09-02 Novartis Ag Méthodes de production de cellules exprimant un récepteur antigénique chimérique
KR20220155338A (ko) 2020-03-19 2022-11-22 암젠 인크 뮤신 17에 대한 항체 및 이의 용도
CN115894703A (zh) 2020-04-29 2023-04-04 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
UY39191A (es) 2020-04-29 2021-11-30 Teneobio Inc Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CA3182697A1 (fr) 2020-05-11 2021-11-18 Janssen Biotech, Inc. Methodes de traitement d'un myelome multiple
AU2021274151A1 (en) 2020-05-19 2023-02-02 Janssen Biotech, Inc. Compositions comprising a T cell redirection therapeutic and a VLA-4 adhesion pathway inhibitor
IL298473A (en) 2020-06-11 2023-01-01 Novartis Ag zbtb32 inhibitors and uses thereof
EP4171750A1 (fr) 2020-06-30 2023-05-03 Teneobio, Inc. Anticorps multi-spécifiques se liant à bcma
KR20230058427A (ko) 2020-08-21 2023-05-03 노파르티스 아게 Car 발현 세포의 생체내 생성을 위한 조성물 및 방법
US20230398147A1 (en) 2020-09-16 2023-12-14 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
WO2022103781A1 (fr) 2020-11-10 2022-05-19 Amgen Inc. Procédés d'administration d'une molécule de liaison à bcma x cd3
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
WO2022135468A1 (fr) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 Anticorps bispécifique anti-bcma×cd3 et son utilisation
CN114763383A (zh) * 2021-01-13 2022-07-19 博生吉医药科技(苏州)有限公司 靶向人bcma的单克隆抗体及其应用
US20220233690A1 (en) 2021-01-28 2022-07-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
GB2623199A (en) 2021-04-08 2024-04-10 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof
EP4330381A1 (fr) 2021-04-27 2024-03-06 Novartis AG Système de production de vecteurs viraux
EP4347656A1 (fr) 2021-05-28 2024-04-10 GlaxoSmithKline Intellectual Property Development Limited Polythérapies pour traiter le cancer
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
WO2023012669A2 (fr) 2021-08-03 2023-02-09 Glaxosmithkline Intellectual Property Development Limited Compositions biopharmaceutiques et procédé de cartographie peptidique de marquage isotopique stable
AR126838A1 (es) 2021-08-20 2023-11-22 Novartis Ag Métodos para preparar células que expresan receptores de antígeno quiméricos
WO2023057893A1 (fr) 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Polythérapies pour le traitement du cancer
WO2023144702A1 (fr) 2022-01-25 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Polythérapie contre le cancer
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2024089639A1 (fr) 2022-10-26 2024-05-02 Novartis Ag Formulations lentivirales

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US556A (en) 1838-01-09 Machine foe
US4816A (en) 1846-10-17 Bell machinery for hotels
US5013A (en) 1847-03-13 Improvement in apparatus for the manufacture of malleable iron
US567A (en) 1838-01-09 Machine for r-uibbii
US1985A (en) 1841-02-18 Charles m
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
WO1998052976A1 (fr) 1997-05-21 1998-11-26 Biovation Limited Procede de production de proteines non immunogenes
JP2001518328A (ja) 1997-10-01 2001-10-16 ボストン サイエンティフィック リミテッド 拡張システムおよび関連方法
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
PL393286A1 (pl) 1999-01-07 2011-06-06 Zymogenetics, Inc. Rozpuszczalny receptor BR43x2 i sposoby jego zastosowania
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
KR20090016772A (ko) 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP1280826B1 (fr) * 2000-05-12 2007-05-02 Amgen Inc. Polypeptides pour inhibir l'activation des cellules b et t induite par april
JP2004533997A (ja) * 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Ｂｃｍａ及びｔａｃｉの両者を結合する抗体
BRPI0410338A (pt) 2003-05-31 2006-05-30 Micromet Ag composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral
AU2004283850C1 (en) 2003-10-16 2011-11-03 Amgen Research (Munich) Gmbh Multispecific deimmunized CD3-binders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2554526A1 (fr) * 2004-01-29 2005-08-18 Genentech, Inc. Variants du domaine extracellulaire de bcma et utilisations de ceux-ci
CN1950399A (zh) * 2004-02-16 2007-04-18 麦克罗梅特股份公司 免疫原性较弱的结合分子
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
EP3178850B1 (fr) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprenant des anticorps spécifiques aux espèces croisées et leurs utilisations
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
SI2155783T1 (sl) 2007-04-03 2013-10-30 Amgen Research (Munich) Gmbh Medvrstno specifiäśna cd3-epsilon vezavna domena
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
TR201816277T4 (tr) 2007-04-03 2018-11-21 Amgen Res Munich Gmbh Çapraz-tür-spesifik bağlama alanı.
AU2009239437B2 (en) * 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
MX338038B (es) 2008-10-01 2016-03-30 Amgen Res Munich Gmbh Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas.
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
HUE030090T2 (en) 2008-10-01 2017-04-28 Amgen Res (Munich) Gmbh Species specific PSMAxCD3 bispecific single chain antibody
AU2009299793B2 (en) 2008-10-01 2016-03-10 Amgen Research (Munich) Gmbh Bispecific single chain antibodies with specificity for high molecular weight target antigens
EP3141562A1 (fr) 2009-03-10 2017-03-15 Biogen MA Inc. Anticorps anti-bcma
EP2424567B1 (fr) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
EP3974453A3 (fr) 2010-11-16 2022-08-03 Amgen Inc. Agents et procédés pour traiter les maladies en corrélation avec l'expression bcma
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2731280B8 (fr) 2012-11-07 2019-03-20 Telefonaktiebolaget LM Ericsson (publ) Auto-test intégré en bouclage local
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2762497A1 (fr) 2013-02-05 2014-08-06 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
HUE057220T2 (hu) * 2016-02-03 2022-04-28 Amgen Res Munich Gmbh BCMA és CD3 bispecifikus, T-sejtet kötõ antitest-konstrukciók

Also Published As

Publication number Publication date
MX2014005852A (es) 2014-09-22
US10766969B2 (en) 2020-09-08
CA2849196C (fr) 2021-04-20
US20220356268A1 (en) 2022-11-10
JP6738314B2 (ja) 2020-08-12
EA028162B1 (ru) 2017-10-31
CN104169300A (zh) 2014-11-26
NZ622087A (en) 2016-06-24
US20140348837A1 (en) 2014-11-27
ECSP14004893A (es) 2015-06-30
ECSP14004829A (es) 2015-07-31
JP2014534242A (ja) 2014-12-18
KR102062231B1 (ko) 2020-01-03
EP2780375A1 (fr) 2014-09-24
FR23C1013I1 (fr) 2023-04-14
EA201490932A1 (ru) 2014-09-30
EP2780374A1 (fr) 2014-09-24
US20150023967A1 (en) 2015-01-22
US9340621B2 (en) 2016-05-17
WO2013072415A1 (fr) 2013-05-23
CN104114578B (zh) 2018-10-16
EA201490931A1 (ru) 2014-08-29
HUE046682T2 (hu) 2020-03-30
CN109485729A (zh) 2019-03-19
EP3623385A8 (fr) 2020-05-06
IL232603A0 (en) 2014-06-30
GEP20186928B (en) 2018-11-26
KR20140105758A (ko) 2014-09-02
TW201326214A (zh) 2013-07-01
EP3611193A1 (fr) 2020-02-19
EP2780375B1 (fr) 2019-09-11
IL232636A0 (en) 2014-06-30
MA35450B1 (fr) 2014-09-01
US9150664B2 (en) 2015-10-06
IL260189A (en) 2018-07-31
KR20140105757A (ko) 2014-09-02
AU2012327203A1 (en) 2013-05-30
PT2780375T (pt) 2019-11-12
ES2749451T3 (es) 2020-03-20
ES2751996T3 (es) 2020-04-02
JP2017195889A (ja) 2017-11-02
CN104114578A (zh) 2014-10-22
JP2015504306A (ja) 2015-02-12
US20130156770A1 (en) 2013-06-20
UY34454A (es) 2013-06-28
SG11201400671YA (en) 2014-04-28
KR102229469B1 (ko) 2021-03-18
HRP20191697T1 (hr) 2019-12-13
DK2780375T3 (da) 2019-11-18
SI2780375T1 (sl) 2019-11-29
PL2780375T3 (pl) 2020-01-31
CL2014001254A1 (es) 2014-10-10
ME03521B (fr) 2020-04-20
IL232603B (en) 2018-07-31
TN2014000097A1 (en) 2015-07-01
JP2018050627A (ja) 2018-04-05
MY189544A (en) 2022-02-16
EP3623385A1 (fr) 2020-03-18
BR112014010940A2 (pt) 2017-05-16
JP2020202838A (ja) 2020-12-24
MX2014005851A (es) 2015-01-19
LT2780375T (lt) 2019-11-11
JP7250736B2 (ja) 2023-04-03
AP2014007529A0 (en) 2014-03-31
RS59373B1 (sr) 2019-11-29
US20220064336A1 (en) 2022-03-03
SG10201704483RA (en) 2017-07-28
MA35449B1 (fr) 2014-09-01
ZA201401615B (en) 2017-08-30
EP2780374B1 (fr) 2019-08-21
KR20210032012A (ko) 2021-03-23
MX349396B (es) 2017-07-26
KR102346029B1 (ko) 2022-01-03
PE20141564A1 (es) 2014-11-29
TN2014000121A1 (en) 2015-07-01
TWI679212B (zh) 2019-12-11
JP6231007B2 (ja) 2017-11-15
CA2850591A1 (fr) 2013-05-23
UY34453A (es) 2013-06-28
US9598500B2 (en) 2017-03-21
BR112014010630B1 (pt) 2022-10-04
US20220251243A1 (en) 2022-08-11
CY1122543T1 (el) 2021-01-27
WO2013072406A1 (fr) 2013-05-23
AR088883A1 (es) 2014-07-16
BR112014010630A2 (pt) 2017-04-25
SG11201401729PA (en) 2014-09-26
UA116766C2 (uk) 2018-05-10
US20130156769A1 (en) 2013-06-20
CA2849196A1 (fr) 2013-05-23
KR20200003934A (ko) 2020-01-10
JP6378087B2 (ja) 2018-08-22
PH12014501091A1 (en) 2014-07-28

Similar Documents

Publication Publication Date Title
IL260189A (en) Communicating molecules for bcma and cd3
IL270223B (en) Molecules that specifically bind tdp–43
IL268886A (en) Dual-specific T cells that activate antigen-binding molecules
HRP20181355T1 (hr) Bispecifične molekule koje se vežu na antigen
HK1223629A1 (zh) 結合分子
HK1203207A1 (en) Binding molecules specific for her3 and uses thereof her3
AP2015008266A0 (en) 1L-18 binding molecules
AP2014007497A0 (en) Binding molecules for BCMA and CD3